Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: BMcV who wrote (2301)	4/14/1999 10:25:00 AM
From: j_fir2	Read Replies (1) \| Respond to of 10280

<<AZA's problems with Ditropan shouldn't be weighing on us>>--I don't know if I agree with that. SEPR's price was steady or slightly higher at the open, it took that hit later in the day, perhaps after that analyst's report came out. SEPR is preparing to go into Phase II trials on the ICE oxybutynin, and the market model that has enticed so many newcomers depends upon riding the coattails of blockbusters (or else how to justify the price, burn rate, etc.) I think some of the new investors aren't fully confident of their new holding. And as Mazen said, they were mostly small blocks. Plus, there's options expiration, and the first one after the FDA approval, no? Thanks Steve for bringing that AZA news to our attention.